14
Volltext
19
Goossens, M.E., Buntinx, F., Joniau, S., Ackaert, K., Ameye, F., Billiet, I., Braeckman, J., Breugelmans, A., Darras, J., Dilen, K., Goeman, L., Kellen, E., Tombal, B., van Bruwaene, S., van Cleyenbreuge, B., van der Aa, F., Vekemans, K., van Poppel, H., Zeegers, M.P.
Veröffentlicht in: Goossens , M E , Buntinx , F , Joniau , S , Ackaert , K , Ameye , F , Billiet , I , Braeckman , J , Breugelmans , A , Darras , J , Dilen , K , Goeman , L , Kellen , E , Tombal , B , van Bruwaene , S , van Cleyenbreuge , B , van der Aa , F , Vekemans , K , van Poppel , H & Zeegers , M P 2012 , ' Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium ' , BMC Urology , vol. 12 , no. 1 , 8 , pp. 8 . https://doi.org/10.1186/1471-2490-12-8;
2012
Volltext